  With the application of hematopoietic stem cell transplantation and new
drugs, the progression-free survival rate and overall survival rate of multiple
myeloma have been greatly improved, but it is still considered as a kind of
disease that cannot be completely cured. Many patients have disease recurrence
after complete remission, which is rooted in the presence of minimal residual
disease MRD in patients. Studies have shown that positive MRD is an independent
adverse prognostic factor affecting survival, so MRD detection is an important
indicator to judge the prognosis of patients and guide clinical treatment. At
present, multipa-rameter flow cytometry (MFC), polymerase chain reaction (PCR),
positron emission tomography (positron emission) Several techniques, such as
PET/computer tomography (CT), have been used for MRD detection of multiple
myeloma.However, there is still no cure for the disease. "IFM2013-04" four
clinical studies confirmed for the first time that proteasome inhibitors (PIs)
and immunomodulatory drugs, The synergism and importance of the combination of
IMiDs in the treatment of MM, the large Phase 3 clinical study SWOG SO777
compared the combination of bortezomib plus lenalidomide and dexamethasone. The
efficacy of VRD and D established the status of VRD first-line treatment of MM,
and due to the good efficacy of CD38 monoclonal antibody in large clinical
studies, combination therapy with VRD has been recommended as the first-line
treatment of MM. However, to explore the clinical value and problems of
applying artificial intelligence bone marrow cell recognition system Morphogo
in the detection of multiple myeloma minimal residual disease (MRD)
